• Team with expertise and previous success

Richard Gomer, Ph.D., scientific founder of Prosia, former scientific founder of Promedior, biologist

  • Tom Meek, Ph.D., scientific founder of Prosia, former World Wide Vice President at GSK, medicinal chemist
    • Dr. Meek will serve as Head of Medicinal Chemistry of Prosia. This role includes design, synthesis, and enzymatic characterization of enzyme inhibitors of human NEU3, oversight of structural biology of NEU3, selectivity and safety profiling of lead compounds, and collaboration on pre-clinical studies of candidate-quality inhibitors.
    • Dr. Meek is a Professor of Biochemistry and Biophysics at Texas A&M University.  The mission of his laboratory is the rational design of enzyme inhibitors.  For instance, the Meek lab discovered a cysteine protease inhibitor that has advanced to Phase II clinical trials within eighteen months.  Prior to joining Texas A&M in 2014, Dr. Meek held numerous world-wide leadership roles in early-stage drug discovery at GlaxoSmithKline Pharmaceuticals, and he has worked in drug discovery at several pharmaceutical companies since 1984.  He was a co-discoverer of the HIV protease, inhibitors of which have  transformed AIDS/HIV into a manageable disease, as well as beta-secretase, the latter enzyme being responsible for amyloid plaque formation in Alzheimer’s Disease.